Strategic Addition To Life Sciences Research Team

New York, December 6, 2018 -- Oppenheimer & Co. Inc. today announced that Kevin DeGeeter joined the Firm as Managing Director and Senior Analyst of the Life Sciences research team. DeGeeter will focus primarily on biotechnology, but will also expand Oppenheimer's presence in molecular diagnostics.

"We are delighted to have Kevin return to the Firm in a senior role on our Life Sciences research team," said Director of Equity Research, John Parks. "Oppenheimer has a long-standing commitment to the biotechnology industry, and Kevin's addition allows us to significantly deepen our domain expertise. His experience in the key subsectors of molecular diagnostics, emerging technologies, infectious diseases, and of course oncology, makes him the ideal addition as we continue to expand our team." 

With over two decades of buy- and sell-side experience, DeGeeter will be responsible for expanding and differentiating Oppenheimer's research product. He previously served as Managing Director at Ladenburg Thalmann and has also held positions at J.P Morgan, Paine Webber, Natixis Bleichroeder, and Manning & Napier Advisors. He spent two years at Oppenheimer previously as a Senior Analyst.

"Right now, the opportunity in biotechnology and molecular diagnostics is tremendous," said DeGeeter. "The rise of sequencing technologies and new reimbursement models allows companies to innovate how they're testing and matching the best drug for the right patient to provide value. Also, the proliferation of antibiotic-resistant bacteria presents new challenges and opportunities for innovation within the space. I look forward to helping our clients capitalize on these trends in personalized medicine and molecular diagnostics." 

DeGeeter earned his bachelor's degree in Economics from Colgate University.